Tuesday, July 9, 2019

CNN MOney & BBC : LSD & Sillicon Valley - PSychedelics that EVERYONE who is bilionaire, is on!


https://problemsolvingexperiment.blogspot.com/2019/05/psychedelic-agents-in-creative-problem.html

 Fallowup:

 Smart Drugs: What Silicon Valley's on

 Can LSD make you a billionaire?

 I did LSD with Steve Jobs

 Microdosing: People who take LSD with breakfast - BBC News

 How MDMA and psychedelic drugs can assist mental health

 SEX DRUGS AND SILICON VALLEY - SMART DRUGS

 LSD Microdosing: The New Silicon Valley Productivity Hack

 Real-life 'Limitless' pill? Silicon Valley entrepreneurs pursue nootropics or 'smart drugs'

 At same time, if Common people tryto Share that to common people.. (DOUBLE life in prison sentence with out possibility of parole):



 The Secrets of Silicon Valley: What Big Tech Doesn't Want You to Know
(or perhaps.. these Who are able.. we Want You to  KNow...)
  https://youtu.be/TbKxUYl3WSE
Posted by at No comments:

Wednesday, May 29, 2019

Microdosing, or micro-dosing for providing brain with naturally needed "vitamines" that we scrape from our food.


Microdosing, & silicon-valley


https://money.cnn.com/2015/01/25/technology/lsd-psychedelics-silicon-valley/index.html







Herbert, who works at Cisco, has been in the tech sphere for decades. For him, geek-dom and psychedelics have intersected since the start of his adult life: The first LSD he took was created in an M.I.T. lab at and consumed at a science fiction convention.
In Silicon Valley, there is a premium on creativity, and tools thought to induce or enhance it are avidly sought. Some view psychedelics as a weapon in the arsenal, a way to approach problems differently.
There's no definitive scientific evidence that LSD or other hallucinogens improve creativity, and the DEA classifies LSD as a "highly addictive", "Schedule I drug"

-  in truth, hallucinogens actually are used to cure addictions and to be defined as "hallucinogen / psychedelics " the substance can not be addictive by defination accepted by DEA high end gov scientists. So there is a slight issue to fix in Law aria and investigate, who have been these forces who have systematically mislead humans about natuarally needed substances like psychedelics - and for what cause/reason. 
Is know, that Soviet Union International Forces have been strongly against psychedelics  and eliminated any kind of reasonable information about these cultures and practises physically and from literature.  Might be becuse hallucinogen have self realization and truth serium kind of effect besides being able to decode information more deeper and connect dots that common mind would not be able for working/thinking "too fast". 
- this is what is my personal logical view on it. 
https://www.amazon.com/Shamans-Coat-Native-History-Siberia/dp/0802713998
(Or perhaps, they just wanted to keep their  Two-Head-Eagle advantage...)
But at no cost i would reccomend any kind of spirit or ritual things, urdinary christian pray or light meditation is sufficient for ordinary trips, understanding the excistance of Creator helps a lot also when one plan to go deeper (more then 125ug ordinary amount). 
----



There is another complete safe way: 

https://en.wikipedia.org/wiki/Microdosing
Microdosing, or micro-dosing, is a technique for studying the behaviour of drugs in humans through the administration of doses so low ("sub-therapeutic") they are unlikely to produce whole-body effects, but high enough to allow the cellular response to be studied. This is called a "Phase 0 study" and is usually conducted before clinical Phase I to predict whether a drug is viable for the next phase of testing. Human microdosing aims to reduce the resources spent on non-viable drugs and the amount of testing done on animals.
Less commonly, the term "microdosing" is also sometimes used to refer to precise dispensing of small amounts of a drug substance (e.g., a powder API) for a drug product (e.g., a capsule),[1] and when the drug substance also happens to be liquid this can potentially overlap what is termed microdispensing. For example, psychedelic microdosing.[2]

Techniques 

The basic approach is to label a candidate drug using the radioisotope carbon-14,[citation needed] then administer the compound to human volunteers at levels typically about 100 times lower than the proposed therapeutic dosage (from around 1 to 100 micrograms but not above).[3]
As only microdose levels of the drug are used, analytical methods are limited. Extreme sensitivity is needed. Accelerator Mass Spectrometry is the most common method for microdose analysis. AMS was developed in the late 1970s from two distinct research threads with a common goal:[citation needed] an improvement in radiocarbon dating that would make efficient use of datable material and that would extend the routine and maximum reach of radiocarbon dating. AMS is routinely used in geochronology and archaeology,  but biological applications began appearing in 1990 mainly due to the work of scientists at Lawrence Livermore National Laboratory. AMS service is now more accessible for biochemical quantitation from several private companies and non-commercial access to AMS is available at the National Institutes of Health (NIH) Research Resource at Lawrence Livermore National Laboratory,  or through the development of smaller affordable spectrometers. AMS does not measure the radioactivity of carbon-14 in microdose samples. AMS, like other mass spectrometry methods, measures ionic species according to mass-to-charge ratio.

Impact of use 

It is reported that 15 of the 20 largest pharmaceutical companies have now used microdosing in drug development, and the use of the technique has been provisionally endorsed by both the European Medicines Agency and the Food and Drug Administration. It was once expected that by 2010, human microdosing would have gained a secure foothold at the discovery-preclinical interface, driven by early measurement of candidate drug behavior in humans and by irrefutable economic arguments. 
In January 2006, the European Union Microdose AMS Partnership Programme (EUMAPP) was launched.  Ten organizations from five different countries (United Kingdom, Sweden, Netherlands, France, and Poland) will study various approaches to the basic AMS technique. The study is set to be published in 2009. 
One of the most meaningful potential outcomes of Phase-0/Microdosing studies is the early termination of development. In 2017, Okour et al published the first example in literature of a termination of an oral drug based on IV microdose data.[4] This study provides an example of the application of microdosing in circumstances where pre-clinical data were not sufficient to provide accurate information to guide first-in-human (FIH) study design.

References 


^ Tablets & Capsules, March 2009. "Micro-dosing equipment fills niche in R&D, clinical trial materials".
^ "Everything You Wanted to Know About Microdosing (But Were Afraid to Ask)". The Huffington Post. 13 January 2016.
^ [1] Animal Testing Perspectives: Microdosing
^ Okour, Malek; Derimanov, Geo; Barnett, Rodger; Fernandez, Esther; Ferrer, Santiago; Gresham, Stephanie; Hossain, Mohammad; Gamo, Francisco-Javier; Koh, Gavin; Pereira, Adrian; Rolfe, Katie; Wong, Deborah; Young, Graeme; Rami, Harshad; Haselden, John (2018). "A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers". British Journal of Clinical Pharmacology. 84 (3): 482–489. doi:10.1111/bcp.13476. PMC 5809343. PMID 29168205.
  • "The use of accelerator mass spectrometry to obtain early human ADME/PK data" G Lappin & R C Garner Expert Opinion in Pug Metabolite and Toxic (2005) 1(1):23-31
  • "Improved early clinical development through human microdosing studies" I Wilding & J Bell Drug Discovery Today 2005 July 1;10(13):890-4
  • "New ultrasensitive detection technologies and techniques for use in microdosing studies" G Lappin, C Wagner, O Langer & N van de Merbel Bioanalysis 2009 May 1(2):357–366 doi:10.4155/bio.09.40

External links 


Review article on microdosing as a means of reducing the use of animals in drug testing (PDF format)
EU announcement of EUMAPP project




Posted by at No comments:
Labels: , ,

Psychedelic agents in creative problem-solving experiment [1966] study with top scientists.



Problem-solving Experiment
- Important to read once for everyone who's life is benafiting from production, thinking or creativity



The first group consisted of four people with professional experience in electrical engineering, engineering design, engineering management and psychology. They were given 50 micrograms of LSD. The second group consisted of four research engineers, three with a background in electronics and one in mechanics. They were given 100 milligrams of mescaline.
//
Each group of four subjects met for an evening session several days before the experiment. They received instructions and introduced themselves and their unsolved problems to the group. Approximately one hour of pencil-and-paper tests were also administered. At the beginning of the day of the experiment session, subjects were given 200 milligrams of mescaline sulphate (a moderately light dose compared to the doses used in experiments to induce mystical experiences).

Results 

Solutions obtained in the experiment include:[3][5][6]
  • a new approach to the design of a vibratory microtome
  • a commercial building design, accepted by the client
  • space probe experiments devised to measure solar properties
  • design of a linear electron accelerator beam-steering device
  • engineering improvement to a magnetic tape recorder
  • a chair design, modeled and accepted by the manufacturer
  • a letterhead design, approved by the customer
  • a mathematical theorem regarding NOR gate circuits
  • completion of a furniture-line design
  • a new conceptual model of a photon, which was found useful
  • design of a private dwelling, approved by the client
  • insights regarding how to use interferometry in medical diagnosis application sensing heat distribution in the human body
The participants also reported following experiences of enhanced functioning: low inhibition and anxiety, capacity to restructure problem in larger context, enhanced fluency and flexibility of ideation, heightened capacity for visual imagery and fantasy, increased ability to concentrate, heightened empathy with external processes and objects, heightened empathy with people, subconscious data more accessible, association of dissimilar ideas, heightened motivation to obtain closure, visualizing the completed solution.



Full text:
___________

Psychedelic agents in creative problem-solving experiment was a study designed to evaluate whether the use of a psychedelic substance with supportive setting can lead to improvement of performance in solving professional problems. The altered performance was measured by subjective reports, questionnaires, the obtained solutions for the professional problems and psychometric data using the Purdue Creativity, the Miller Object Visualization, and the Witkins Embedded Figures tests.[1] This experiment was a pilot that was to be followed by control studies as part of exploratory studies on uses for psychedelic drugs, that were interrupted early in 1966 when the Food and Drug Administrationdeclared a moratorium on research with human subjects, as a strategy in combating illicit use.[2]

Procedure[edit]

Some weeks before the actual experiment, a preliminary experiment was conducted. It consisted of two sessions with four participants in each. The groups worked on two problems chosen by the research personnel. The first group consisted of four people with professional experience in electrical engineering, engineering design, engineering management and psychology. They were given 50 micrograms of LSD. The second group consisted of four research engineers, three with a background in electronics and one in mechanics. They were given 100 milligrams of mescaline. Both groups were productive in ideation but, according to Fadiman, the fact that the participants didn't have actual personal stake in the outcome of the session negatively affected the actualization of the ideas. This is why the actual study focused on personal professional problems that the participants were highly motivated to tackle.[3]
The experiment was carried out in 1966 in a facility of International Foundation for Advanced Study, Menlo Park, California, by a team including Willis Harman, Robert H. McKim, Robert E. Mogar, James Fadiman and Myron Stolaroff. The participants of the study consisted of 27 male subjects engaged in a variety of professions: sixteen engineers, one engineer-physicist, two mathematicians, two architects, one psychologist, one furniture designer, one commercial artist, one sales manager, and one personnel manager. Nineteen of the subjects had had no previous experience with psychedelics. Each participant was required to bring a professional problem they had been working on for at least 3 months, and to have a desire to solve it.
Commonly observed characteristics of the psychedelic experience seemed to operate both for and against the hypothesis that the drug session could be used for performance enhancement. The research was therefore planned so as to attempt to provide a setting that would maximize improved functioning, while minimizing effects that might hinder effective functioning.[4] Each group of four subjects met for an evening session several days before the experiment. They received instructions and introduced themselves and their unsolved problems to the group. Approximately one hour of pencil-and-paper tests were also administered. At the beginning of the day of the experiment session, subjects were given 200 milligrams of mescaline sulphate (a moderately light dose compared to the doses used in experiments to induce mystical experiences). After some hours of relaxation, subjects were given tests similar to the ones on the introduction day. After the tests, subjects had four hours to work on their chosen problems. After the working phase, the group would discuss their experiences and review the solutions they had come up with. After this, the participants were driven home. Within a week after the session, each participant wrote a subjective account of his experience. Six weeks further, subjects again filled in questionnaires, this time concentrating on the effects on post-session creative ability and the validity and reception of the solutions conceived during the session. This data was in addition to the psychometric data comparing results of the two testing periods.




Criticism 
According to a recent unpublished review by Matthew J. Baggott, PhD, the experimenters co-administered methamphetamine as an "energizer" along with the mescaline. This went mysteriously unreported in Fadiman's published work.
"[T]he preliminary report of the study indicates that participants received methamphetamine and chlordiazepoxide along with the mescaline: 'In the individual sessions the drug regime consists of psychic energizers and a psychedelic drug (200 mg. of mescaline sulphate in these experiments), usually with additional energizer at mid-day' (Fadiman et al. 1965, p 4). The nature of these energizers is clarified later in the report where methedrine (methamphetamine) and librium (chlordiazepoxide) are explicitly mentioned (ibid, p B-1). Because the co-administration of other drugs was not described in the peer-reviewed publication by Harman et al. in Psychological Reports, very few subsequent commentators have noted this confound (Krippner (1968) notes the use of 'energizers' without comment)"[7] p.8

Related research[edit]

In the overview of the experiment, Harman and Fadiman mention that experiments on specific performance enhancement through directed use of psychedelics have gone on in various countries of the world, on both sides of the Iron Curtain.[8]
In the book LSD — The Problem-Solving Psychedelic, Stafford and Golightly write about a man engaged in naval research, working with a team under his direction on the design of an anti-submarine detection device for over five years without success. He contacted a small research foundation studying the use of LSD. After a few sessions of learning to control the fluidity of the LSD state (how to stop it, how to start it, how to turn it around) he directed his attention to the design problem. Within ten minutes he had the solution he had been searching for. Since then, the device has been patented by the U.S., and Navy and Naval personnel working in this area have been trained in its use.[9]
In 1999 Jeremy Narby, an anthropologist specialized in amazonian shamanism, acted as a translator for three molecular biologists who travelled to the Peruvian Amazon to see whether they could obtain bio-molecular information in the visions they had in sessions orchestrated by an indigenous shaman. Narby recounts this preliminary experiment and the exchange of methods of gaining knowledge between the biologists and indigenous people in his article Shamans and scientists.[10]
In 1991, Denise Caruso, writing a computer column for The San Francisco Examiner went to SIGGRAPH, the largest gathering of computer graphic professionals in the world. She conducted a survey; by the time she got back to San Francisco, she had talked to 180 professionals in the computer graphic field who had admitted taking psychedelics, and that psychedelics are important to their work; according to mathematician Ralph Abraham.[11][12]
James Fadiman is currently conducting a study on psychedelic micro-dosing for improving normal functioning.[13] Micro-dosing (or sub-perceptual dosing) means taking sub-threshold dose, which for LSD is 10-20 micrograms. The purpose of micro-dosing is not intoxication but enhancement of normal functionality (see nootropic). In this study the volunteers self-administer the drug approximately every third day. They then self-report perceived effects on their daily duties and relationships. Volunteers participating in the study include a wide variety of scientific and artistic professionals and students. So far the reports suggest that, in general, the subjects experience normal functioning but with increased focus, creativity and emotional clarity and slightly enhanced physical performance. Albert Hofmann was also aware of micro-dosing and has called it the most under-researched area of psychedelics.[14]
Since the 1930s, ibogaine was sold in France in 8 mg tablets in the form of Lambarène, an extract of the Tabernanthe manii plant. 8 mg of ibogaine could be considered a microdose since doses in ibogatherapy and -rituals vary in the range of 10 mg/kg to 30 mg/kg adding usually up to 1000 mg.[15] Lambarène was advertised as a mental and physical stimulant and was "...indicated in cases of depression, asthenia, in convalescence, infectious disease, [and] greater than normal physical or mental efforts by healthy individuals". The drug enjoyed some popularity among post World War II athletes, but was eventually removed from the market, when the sale of ibogaine-containing products was prohibited in 1966.[16] In the end of 1960's The International Olympic Committee banned ibogaine as a potential doping agent.[17] Other psychedelics have also been reported to have been used in similar way as doping.[18]
In 1948, Swiss pharmacologist Peter N. Witt started his research on the effect of drugs on spiders. Witt tested spiders with a range of psychoactive drugs, including amphetamine, mescaline, strychnine, LSD, and caffeine. All the drugs tested reduced web regularity except for small doses (0.1–0.3 µg) of LSD, which increased web regularity.[19]



Results 

Solutions obtained in the experiment include:[3][5][6]
  • a new approach to the design of a vibratory microtome
  • a commercial building design, accepted by the client
  • space probe experiments devised to measure solar properties
  • design of a linear electron accelerator beam-steering device
  • engineering improvement to a magnetic tape recorder
  • a chair design, modeled and accepted by the manufacturer
  • a letterhead design, approved by the customer
  • a mathematical theorem regarding NOR gate circuits
  • completion of a furniture-line design
  • a new conceptual model of a photon, which was found useful
  • design of a private dwelling, approved by the client
  • insights regarding how to use interferometry in medical diagnosis application sensing heat distribution in the human body
The participants also reported following experiences of enhanced functioning: low inhibition and anxiety, capacity to restructure problem in larger context, enhanced fluency and flexibility of ideation, heightened capacity for visual imagery and fantasy, increased ability to concentrate, heightened empathy with external processes and objects, heightened empathy with people, subconscious data more accessible, association of dissimilar ideas, heightened motivation to obtain closure, visualizing the completed solution.








See also 

References 


    ^ Harman, W. W.; McKim, R. H.; Mogar, R. E.; Fadiman, J.; Stolaroff, M. J. (1966). "Psychedelic agents in creative problem-solving: A pilot study". Psychological Reports. 19(1): 211–227. doi:10.2466/pr0.1966.19.1.211. PMID 5942087.
    ^ Tim Doody's article "The heretic" about doctor James Fadiman's experiments on psychedelics and creativity
    ^ Jump up to:a b "The Psychedelic explorer's guide - Safe, Therapeutic and Sacred Journeys. Chapter 12: Group Problem-Solving Sessions" James Fadiman, Willis Harman 2011, pages 167-177.
    ^ "The Psychedelic explorer's guide - Safe, Therapeutic and Sacred Journeys. Chapter 9: Breaktgrough Research: Selective Enhancement of Creative Capacaties" James Fadiman, Willis Harman 2011, pages 122. Table 9.1
    ^ Scientific Problem Solving with Psychedelics, James Fadiman, YouTube
    ^ Psychedelic agents in creative problem solving: A pilot study, W. Harman et al, 1966, Psychological Reports: Volume 19, Issue, pp. 211-227
  1. ^ Baggott, Matthew (June 2015). "Psychedelics and Creativity: a Review of the Quantitative Literature" (PDF). PeerJ PrePrints.
    2. ^ "Selective Enhancement of Specific Capacities Through Psychedelic Training" Willis W. Harman and James Fadiman
    ^ LSD — The Problem-Solving Psychedelic Chapter III. Creative Problem Solving. P.G. Stafford and B.H. Golightly
    ^ Shamans and scientists Archived 2014-03-02 at the Wayback Machine Jeremy Narby; Shamans through time: 500 years on the path to knowledge p. 301-305.
  2. ^ The San Francisco Examiner, August 4th 1991, Denise Caruso
  3. ^ Mathematics and the Psychedelic Revolution - Ralph Abraham
  4. ^Psychedelic Horizons Beyond Psychotherapy Workshop - Part 3/4
    ^ "The Psychedelic explorer's guide - Safe, Therapeutic and Sacred Journeys. Chapter 15: Can Sub-Perceptual Doses of Psychedelics Improve Normal Functioning?" James Fadiman, 2011, pages 198-211.
    ^ Manual for Ibogaine Therapy - Screening, Safety, Monitoring & Aftercare Archived2013-03-07 at the Wayback Machine Howard S. Lotsof & Boaz Wachtel 2003
    ^ Ibogaine: A Novel Anti-Addictive Compound - A Comprehensive Literature ReviewJonathan
  5. Freedlander, University of Maryland Baltimore County, Journal of Drug Education and Awareness, 2003; 1:79-98.
  6. ^ Ibogaine - Scientific Literature Overview The International Center for Ethnobotanical Education, Research & Service (ICEERS) 2012
  7. ^ Psychedelics and Extreme Sports James Oroc. MAPS Bulletin - volume XXI - number 1 - Spring 2011.
    8. ^ Rainer F. Foelix (2010). Biology of spiders. Oxford University Press. p. 179. ISBN 978-0199813247.

External links 


Dr. James Fadiman's Microdosing Website
Psychedelic agents in creative problem-solving: a pilot study; Monograph Supplement 2-V19
When Silicon Valley takes LSD, CNN Money 25.1.2015.
Scientific Problem Solving with Psychedelics Fadimans lecture at Psychedelic Science 2013 conference.
James Fadiman interview TTBOOK 20.05.2013.
The Heretic Tim Doody, The Morning News; 26.07.2012.
Jim Fadiman: Psychedelic Research & Creativity Studies. As a part of the MAPS Event for Santa Cruz's First Friday Art Tour on April 6, 2012, Fadiman hosted a discussion on psychedelic research and creativity studies.
Horizons 2011: Jim Fadiman, Ph.D - “New Frontiers In Psychedelic Research: Letting go of the medical model” James Fadimans lecture on his work with psychedelics and the learning model of psychedelic research.
Psychedelics as Entheogens: How to Create and Guide Successful Sessions James Fadimans lecture in the Psychedelic Science in the 21st Century conference in 2010.
National Geographic: lnside LSD James Fadiman interviewed about the experiment in 2009.
Is it time to revisit the role of psychedelic drugs in enhancing human creativity? B. Sessa, Journal of Psychopharmacology 2008; 22; 821.
TED: Tim Brown: The powerful link between creativity and play Tim Brown talks about conclusions of the experiment at the 2008 Serious Play conference.
Notes from the Psychedelic Salon Podcast 042 – “Using Psychedelics for Rational Work” From the Mind States conference in 2003, James Fadiman tells about his early days in psychedelic research.
A Brave New Prescription For Creative Management Michael Schrage, Fortune Magazine; 30.4.2001.
BBC Horizon: Psychedelic Science. Willis Harman interviewed about the experiment in 1997.
People on Psychedelics Quotes of influential people on their psychedelic experiences.

From sec 52:

Posted by at No comments:
Subscribe to: Posts (Atom)